Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 6,426,426
- Total 13F shares
- 39,727,815
- Share change
- +17,967,980
- Total reported value
- $25,433,377
- Price per share
- $0.64
- Number of holders
- 37
- Value change
- +$11,324,174
- Number of buys
- 15
- Number of sells
- 14
Report period
Q4 2025
Institutions
37
Top holders
10
XLO full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
13D/G
13F
|
Company |
20%
|
14,517,678
|
$9,581,667 | +$2,576,464 | 31 Dec 2025 | |
| Coastlands Capital LP |
13D/G
|
— |
10%
|
5,346,069
|
$3,742,248 | $0 | 04 Dec 2025 | |
| AbbVie Inc. |
13D/G
|
— |
9%
|
4,347,826
|
$3,304,348 | $0 | 11 Feb 2025 | |
| STEMPOINT CAPITAL LP |
13D/G
|
— |
8.4%
|
6,030,028
|
$3,979,818 | +$1,339,818 | 31 Dec 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
6.7%
|
4,676,472
|
$3,086,472 | -$2,286,600 | 31 Dec 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
71%
|
4,566,817
|
$3,848,457 | — | 30 Sep 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
23%
|
1,483,758
|
$1,250,363 | — | 30 Sep 2025 | |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
3/4/5
|
Company · 10%+ Owner |
23%
|
1,475,121
|
$1,243,084 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
20%
|
1,255,692
|
$1,058,549 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
15%
|
961,917
|
$810,607 | — | 30 Sep 2025 | |
| AJU IB Investment Co., Ltd. |
13F
|
Company |
10%
|
667,742
|
$595,559 | — | 30 Sep 2025 | |
| FMR LLC |
3/4/5
13F
|
Other* · Company |
8%
from 13F
|
1,907,670
|
$1,583,366 | — | 26 Oct 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
5.1%
|
328,972
|
$277,257 | — | 30 Sep 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
5.1%
|
328,794
|
$277,075 | — | 30 Sep 2025 | |
| Trustees of Columbia University in the City of New York |
13F
|
Company |
3.9%
|
249,635
|
$210,442 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
3.2%
|
204,700
|
$172,501 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
3.1%
|
198,859
|
$167,578 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.6%
|
163,890
|
$138,110 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.4%
|
87,790
|
$73,981 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
1.2%
|
76,045
|
$64,083 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1%
|
66,609
|
$56,131 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.87%
|
56,081
|
$47,259 | — | 30 Sep 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.5%
|
32,130
|
$27,076 | — | 30 Sep 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.48%
|
31,000
|
$26,124 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.46%
|
29,689
|
$25,019 | — | 30 Sep 2025 | |
| Aptus Capital Advisors, LLC |
13F
|
Company |
0.39%
|
25,000
|
$21,068 | — | 30 Sep 2025 | |
| Mariner, LLC |
13F
|
Company |
0.39%
|
25,000
|
$21,068 | — | 30 Sep 2025 | |
| SevenBridge Financial Group, LLC |
13F
|
Company |
0.39%
|
25,000
|
$19,333 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.38%
|
24,736
|
$20,000 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.29%
|
18,761
|
$15,810 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.21%
|
13,652
|
$11,509 | — | 30 Sep 2025 | |
| Dunhill Financial, LLC |
13F
|
Company |
0.16%
|
10,274
|
$8,658 | — | 30 Sep 2025 | |
| INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV |
13F
|
Company |
0.16%
|
10,000
|
$8,427 | — | 30 Sep 2025 | |
| Pinnacle Financial Group, LLC / IL |
13F
|
Company |
0.16%
|
10,000
|
$8,427 | — | 30 Sep 2025 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0.05%
|
3,300
|
$2,782 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.03%
|
2,037
|
$1,717 | — | 30 Sep 2025 | |
| Key FInancial Inc |
13F
|
Company |
0.01%
|
830
|
$691 | — | 30 Sep 2025 | |
| Private Wealth Management Group, LLC |
13F
|
Company |
0%
|
310
|
$262 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
258
|
$217 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
246
|
$207 | — | 30 Sep 2025 | |
| Yekaterina Chudnovsky |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
7,000,000
|
$5,320,000 | — | 07 Jun 2024 | |
| SV7 Impact Medicine Fund LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,227,264
|
$2,678,630 | — | 26 Oct 2021 | |
| James E. Flynn |
3/4/5
|
Possible Member of 10% Group, 10%+ Owner |
—
class O/S missing
|
2,287,944
|
$1,898,994 | — | 26 Oct 2021 | |
| Atlas Venture Fund XI, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,754,109
|
$1,762,629 | — | 08 Feb 2024 | |
| RiverVest Venture Fund IV, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,441,444
|
$1,196,399 | — | 26 Oct 2021 | |
| Rock Springs Capital Management LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,256,472
|
$1,042,872 | — | 26 Oct 2021 | |
| BAY CITY CAPITAL LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,129,490
|
$937,477 | — | 26 Oct 2021 | |
| Merck KGaA |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
680,825
|
$565,085 | — | 26 Oct 2021 | |
| Alexandria Venture Investments, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
166,423
|
$138,131 | — | 26 Oct 2021 | |
| Simon M. Tomlinson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
131,117
|
$108,827 | — | 21 Oct 2021 |
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q4 2025
As of 31 Dec 2025,
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,727,815 shares.
The largest 10 holders included
GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, Frazier Life Sciences Management, L.P., Point72 Asset Management, L.P., Sio Capital Management, LLC, STEMPOINT CAPITAL LP, Merck & Co., Inc., VANGUARD GROUP INC, Empery Asset Management, LP, and Ghisallo Capital Management LLC.
This page lists
37
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
36
Q4 2025 holders
37
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.